Hanna Dahlstrand

About me
Publications
Grants
CV
Public outreach and news

About me

Hanna Dahlstrand is associate professor in oncology and senior physician in
oncology and gynecological oncology at Theme Cancer, Karolinska University Hospital. She is research team leader in group Östman, . The research focuses on clinical and translational research in gynecologic cancer.

Articles

Article: CANCER CAUSES AND CONTROL. 2024;35(8):1101-1109
Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Skoeld C; Corvigno S; Dahlstrand H; Enblad G; Mezheyeuski A; Sundstroem-Poromaa I; Stalberg K; Tolf A; Glimelius I; Koliadi A
Article: THE LANCET. 2024;403(10421):31-43
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Oaknin A; Gladieff L; Martinez-Garcia J; Villacampa G; Takekuma M; De Giorgi U; Lindemann K; Woelber L; Colombo N; Duska L; Leary A; Godoy-Ortiz A; Nishio S; Angelergues A; Rubio MJ; Farinas-Madrid L; Yamaguchi S; Lorusso D; Ray-Coquard I; Manso L; Joly F; Alarcon J; Follana P; Romero I; Lebreton C; Perez-Fidalgo JA; Yunokawa M; Dahlstrand H; D'Hondt V; Randall L
Journal article: CANCER RESEARCH. 2023;83(8_Supplement):ct235
Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies
Hahn A; Irenaeus S; Wenthe J; Eriksson E; Schiza A; Dahlstrand H; Olsson-Strömberg U; Krause J; Sundin A; Sandin L; Jarblad JL; Liljefors MG; Rowinsky E; Loskog A; Ullenhag GJ
Article: SEMINARS IN CANCER BIOLOGY. 2022;86(Pt 3):207-223
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
Journal article: CANCER RESEARCH. 2021;81(22_Supplement):po-018-po-018
Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus
Wenthe J; Eriksson E; Sandin L; Lövgren T; Jarblad JL; Dahlstrand H; Olsson-Strömberg U; Schiza A; Sundin A; Irenaeus S; Rowinsky E; Ullenhag G; Loskog A
Article: EBIOMEDICINE. 2021;65:103269
The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types
Micke P; Strell C; Mattsson J; Martin-Bernabe A; Brunnstrom H; Huvila J; Sund M; Warnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicien G; Mollevi DG; Edqvist P-H; Reilly AO; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brandstedt J; Sartor H; Malmstrom P-U; Johansson M; Nodin B; Backman M; Lindskog C; Jirstrom K; Mezheyeuski A
Article: ADVANCES IN THERAPY. 2020;37(12):5023-5031
Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c⁺Expression in Tumor
Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
Article: GYNECOLOGIC ONCOLOGY. 2020;159(3):860-868
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
Corvigno S; Mezheyeuski A; De La Fuente LM; Westbom-Freme S; Carlson JW; Fernebro J; Avall-Lundqvist E; Kannisto P; Hedenfalk I; Malander S; Rolny C; Dahlstrand H; Ostman A
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2020;125(4):325-329
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Tholander B; Koliadi A; Botling J; Dahlstrand H; Von Heideman A; Ahlström H; Öberg K; Ullenhag GJ
Article: EMBO MOLECULAR MEDICINE. 2020;12(4):e11177
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer
Moyano-Galceran L; Pietila EA; Turunen SP; Corvigno S; Hjerpe E; Bulanova D; Joneborg U; Alkasalias T; Miki Y; Yashiro M; Chernenko A; Jukonen J; Singh M; Dahlstrand H; Carlson JW; Lehti K
Article: PLOS ONE. 2020;15(7):e0236291
Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers
Yang C; Zhang Y; Chen Y; Ragaller F; Liu M; Corvigno S; Dahlstrand H; Carlson J; Chen Z; Nasman A; Waraky A; Lin Y; Larsson O; Haglund F
Journal article: CLINICAL CANCER RESEARCH. 2019;25(22_Supplement):gmm-041-gmm-041
Abstract GMM-041: OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH
Moyano-Galceran L; Turunen SP; Pietilä E; Alkasalias T; Corvigno S; Hjerpe E; Joneborg U; Bulanova D; Eriksson M; Dahlstrand H; Carlson J; Lehti K
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2018;123(4):225-229
Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines-a survey in Sweden.
Halldorsdottir S; Dahlstrand H; Stålberg K
Article: NATURE BIOMEDICAL ENGINEERING. 2017;1(10):796-806
Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity
Tanaka N; Kanatani S; Tomer R; Sahlgren C; Kronqvist P; Kaczynska D; Louhivuori L; Kis L; Lindh C; Mitura P; Stepulak A; Corvigno S; Hartman J; Micke P; Mezheyeuski A; Strell C; Carlson JW; Moro CF; Dahlstrand H; Ostman A; Matsumoto K; Wiklund P; Oya M; Miyakawa A; Deisseroth K; Uhlen P
Article: THE JOURNAL OF PATHOLOGY: CLINICAL RESEARCH. 2017;3(3):214-224
Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker
Corvigno S; Frodin M; Wisman GBA; Nijman HW; Van der Zee AGJ; Jirstrom K; Nodin B; Hrynchyk I; Edler D; Ragnhammar P; Johansson M; Dahlstrand H; Mezheyeuski A; Ostman A
Article: ACTA ONCOLOGICA. 2016;55(12):1467-1476
Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO
Derogar M; Dahlstrand H; Carlsson S; Bjartell A; Hugosson J; Axen E; Johansson E; Lagerkvist M; Nyberg T; Stranne J; Thorsteinsdottir T; Wallerstedt A; Haglind E; Wiklund P; Steineck G
Article: LAKARTIDNINGEN. 2016;113:D4WM
[Difficult discussions with patients practiced at course with actors. A carefully planned strategy helps both physician and patient].
Danielsson A; Dahlstrand H; Edvinsson F; Tranberg M; Wrangsjö A; Fürst C-J
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY. 2016;35(3):256-263
A Cell Type Independent Binary Grading System Does Not Significantly Improve Endometrial Biopsy Interpretation
Nastic D; Kahlin F; Dahlstrand H; Carlson JW
Article: ONCOTARGET. 2016;7(14):18573-18584
Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival
Corvigno S; Wisman GBA; Mezheyeuski A; van der Zee AGJ; Nijman HW; Avall-Lundqvist E; Ostman A; Dahlstrand H
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2012;47(4):397-406
Risk factors and chemoprevention in Barrett's esophagus - an update
Winberg H; Lindblad M; Lagergren J; Dahlstrand H
Article: PLOS ONE. 2012;7(10):e46538
Prevalence of Human Papillomavirus (HPV) in Oesophageal Squamous Cell Carcinoma in Relation to Anatomical Site of the Tumour
Lofdahl HE; Du J; Nasman A; Andersson E; Rubio CA; Lu Y; Ramqvist T; Dalianis T; Lagergren J; Dahlstrand H
Article: INTERNATIONAL JOURNAL OF CANCER. 2009;125(2):362-366
Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma?
Nasman A; Attner P; Hammarstedt L; Do J; Eriksson M; Giraud G; Ahrlund-Richter S; Marklund L; Romanitan M; Lindquist D; Ramqvist T; Lindholm J; Sparen P; Ye W; Dahistrand H; Munck-Wikland E; Dalianis T
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(20):3372-3379
Disclosure of incurable illness to spouses:: Do they want to know?: A Swedish population-based follow-up study
Dahlstrand H; Hauksdottir A; Valdimarsdottir U; Fuerst C-J; Bergmark K; Steineck G
Article: ANTICANCER RESEARCH. 2008;28(4B):2077-2080
Human papillomavirus frequency in oral and oropharyngeal cancer in greece
Romanitan M; Nasman A; Ramqvist T; Dahlstrand H; Polykretis L; Vogiatzis P; Vamvakas P; Tasopoulos G; Valavanis C; Arapantoni-Dadioti P; Banis K; Dalianis T
Article: MOLECULAR ONCOLOGY. 2007;1(3):350-355
Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7
Lindquist D; Romanitan M; Hammarstedt L; Naesman A; Dahistrand H; Lindholm J; Oneloev L; Ramqvist T; Ye W; Munck-Wikland E; Dalianis T
Article: ACTA OTO-LARYNGOLOGICA. 2007;127(9):988-992
The incidence of tonsillar cancer in Sweden is increasing
Hammarstedt L; Dahlstrand H; Lindquist D; (Dahlgren) LO; Ryott M; Luo J; Dalianis T; Ye W; Munck-Wikland E
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2007;133(9):673-678
Alcohol, smoking and human papillomavirus in laryngeal carcinoma:: a Nordic prospective multicenter study
Koskinen WJ; Brondbo K; Dahlstrand HM; Luostarinen T; Hakulinen T; Leivo I; Molijn A; Quint WG; Roysland T; Munck-Wikland E; Makitie AA; Pyykko I; Dillner J; Vaheri A; Aaltonen L-M
Article: INTERNATIONAL JOURNAL OF CANCER. 2006;119(11):2620-2623
Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer
Hammarstedt L; Lindquist D; Dahlstrand H; Romanitan M; Onelov (Dahlgren) L; Joneberg J; Creson N; Lindholm J; Ye W; Dalianis T; Munck-Wikland E
Article: ANTICANCER RESEARCH. 2006;26(3B):2205-2208
Molecular and virological studies on a rare case of biliary papillomatosis
Gunven P; Auer G; Gerdes U; Dahlstrand HM; Lewensohn-Fuchs I; Dalianis T
Article: ANTICANCER RESEARCH. 2005;25(6C):4375-4383
P16^INK4a correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma
Dahlstrand HM; Lindquist D; Björnestål L; Ohlsson A; Dalianis T; Munck-Wikland E; Elmberger G
Article: JOURNAL OF GENERAL VIROLOGY. 2005;86(Pt 6):1695-1702
Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment
Szeps M; Dahlgren L; Aaltonen LM; Öhd J; Kanter-Lewenshon L; Dahlstrand H; Munck-Wikland E; Grandér D; Dalianis T
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;112(6):1015-1019
Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients
Dahlgren L; Dahlstrand H; Lindquist D; Högmo A; Björnestål L; Lindholm J; Lundberg B; Dalianis T; Munck-Wikland E
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;107(2):244-249
Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors
Dahlgren L; Mellin H; Wangsa D; Heselmeyer-Haddad K; Björnestål L; Lindholm J; Munck-Wkland E; Auer G; Ried T; Dalianis T
Article: ANTICANCER RESEARCH. 2003;23(3C):2821-2828
Human papillomavirus and DNA ploidy in tonsillar cancer - Correlation to prognosis
Mellin H; Friesland S; Auer G; Dalianis T; Munck-Wikland E
Article: INTERNATIONAL JOURNAL OF CANCER. 2002;102(2):152-158
Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer
Mellin H; Dahlgren L; Munck-Wikland E; Lindholm J; Rabbani H; Kalantari M; Dalianis T
Article: ANTICANCER RESEARCH. 2001;21(1B):529-534
Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma - Relation to radiotherapy response and survival
Friesland S; Mellin H; Munck-Wikland E; Nilsson A; Lindholm J; Dalianis T; Lewensohn R
Article: INTERNATIONAL JOURNAL OF CANCER. 2000;89(3):300-304
Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival
Mellin H; Friesland S; Lewensohn R; Dalianis T; Munck-Wikland E
Article: IN VIVO. 1998;12(2):143-148
Adult X-linked immunodeficiency (XID) mice, IgM^-/- single knockout and IgM^-/-CD8⁺ double knockout mice do not clear polyomavirus infection
Berke Z; Mellin H; Heidari S; Wen T; Berglöf A; Klein G; Dalianis T
Show more

All other publications

Conference publication: 2022;:a411.1-a4a411
2022-RA-1007-ESGO High expression of FAP+ cancer-associated fibroblasts predict poor outcome in patients with high-grade serous ovarian cancer with high CD8-postive T-cell infiltration
Fernebro J; Corvigno S; Mezheieusky A; Karlsson JS; Fuente LMDL; Westbom-Fremer SM; Carlson J; Kannisto PM; Hedenfalk IM; Malander SM; Östman A; Dahlstrand H
Conference publication: 2020;:a70-a71
364 Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by brcawt status: prima/ENGOT-OV26/GOG-3012 study
Braicu EI; Pothuri B; Pérez-Fidalgo JA; O’malley D; Honhon B; Graybill W; Fabbro M; Dahlstrand H; Gupta D; Monk BJ
Conference publication: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2020;30(Suppl 4):a69-a70
347 Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial
Dahlstrand H; Pothuri B; Graybill W; de La Motte Rouge T; Mccormick C; Heitz F; Baurain J-F; Yong L; Monk BJ; González-Martin A
Preprint: SSRN ELECTRONIC JOURNAL. 2020
Stroma Amount in Human Cancer
Micke P; Strell C; Matttsson J; Brunnström H; Huvila J; Sund M; Wärnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicién G; Molleví DG; Edqvist P-H; O´Reilly A; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brändstedt J; Sartor H; Malmström P-U; Johansson M; Nodin B; Backman M; Lindskog C; Jirström K; Mezheyeuski A
Conference publication: CLINICAL CANCER RESEARCH. 2019;25(22):104
OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH
Moyano-Galceran L; Turunen SP; Pietila E; Alkasalias T; Corvigno S; Hjerpe E; Joneborg U; Bulanova D; Eriksson M; Dahlstrand H; Carlson J; Lehti K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e17526
The clinical outcome of FAP plus cancer-associated fibroblasts in high-grade serous ovarian cancer.
Dahlstrand H; Corvigno S; Mezheyeuski A; Carlson JW; Fernebro J; Holzlwimmer G
Corrigendum: NATURE BIOMEDICAL ENGINEERING. 2018;2(1):48
Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity (vol 1, pg 796, 2017)
Tanaka N; Kanatani S; Tomer R; Sahlgren C; Kronqvist P; Kaczynska D; Louhivuori L; Kis L; Lindh C; Mitura P; Stepulak A; Corvigno S; Hartman J; Micke P; Mezheyeuski A; Strell C; Carlson JW; Moro CF; Dahlstrand H; Ostman A; Matsumoto K; Wiklund P; Oya M; Miyakawa A; Deisseroth K; Uhlen P
Conference publication: CANCER RESEARCH. 2016;76:c38
Marker-defined perivascular cells predict prognosis and response to treatment
Corvigno S; Mezheyeuski A; Frodin M; Lindh MB; Guren TK; Pfeiffer P; Kure HE; Ikdahl T; Skovlund E; Tveit KM; Pietras K; Portyanko A; Hrynchyk I; Edler D; Dragomir A; Ponten F; Mulder J; Qvortrup C; Hallstrom M; Ohrling K; Wisman GBA; Avall-Lundqvist E; Johansson M; Harmenberg U; Nijman H; Sandstrom P; Dahlstrand H; Sorbye H; Ginnelius B; Van Der Zee A; Egevad L; Ostman A
Meeting abstract: CANCER RESEARCH. 2015;75:1537
Tumor stroma in serous ovarian cancer; inter and intra patient heterogeneity and impact on survival
Corvigno S; Wisman B; Van der Zee AGJ; Nijman HW; Mezheyeuski A; Lundkvist EA; Ostman A; Dahlstrand H
Book chapter: METHODS OF CANCER DIAGNOSIS, THERAPY, AND PROGNOSIS: METHODS OF CANCER DIAGNOSIS, THERAPY AND PROGNOSIS. 2010;p. 271-283
Role of Human Papillomavirus in Tonsillar Cancer
Munck-Wikland E; Hammarstedt L; Dahlstrand H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):6004
Human papillomavirus (HPV) as a risk factor for the increase in incidence of tonsillar cancer and its expression of E6 and E7
Dahlstrand H; Hammarstedt L; Lindquist D; Ye W; Dalianis T; Munck-Wikland E
Review: ANTICANCER RESEARCH. 2008;28(2B):1133-1138
Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer
Dahlstrand H; Nasman A; Romanitan M; Lindquist D; Ramqvist T; Dalianis T
Review: LAKARTIDNINGEN. 2006;103(44):3366-3368
[Human papillomavirus important factor in the increased incidence of tonsillar cancer].
Munck-Wikland E; Hammarstedt L; Lindquist D; Romanitan M; Dahlstrand H; Dalianis T
Review: LAKARTIDNINGEN. 2006;103(37):2650-2652
[Virus-like particles as cancer vaccine. Great expectations--not only for papillomavirus associated cancer].
Tegerstedt K; Andreasson K; Dahlstrand H; Ramqvist T; Dalianis T
Review: ADVANCES IN CANCER RESEARCH. 2005;93:59-89
Presence and influence of human papillomaviruses (HPV) in tonsillar cancer
Dahstrand HM; Dalianis T
Review: ANTICANCER RESEARCH. 2004;24(3B):1829-1835
Presence of human papillomavirus in tonsillar cancer is a favourable prognostic factor for clinical outcome
Dahlstrand H; Dahlgren L; Lindquist D; Munck-Wikland E; Dalianis T

Grants

The immune system and other cells surrounding the cancer cells in ovarian cancer - how do they affect prognosis and treatment results?
Swedish Cancer Society
1 January 2018
The immune system and other cells surrounding the cancer cells in ovarian cancer - how do they affect prognosis and treatment results?
Swedish Cancer Society
1 January 2017
Increasing the next of kin´s degree of preparedness for her or his spouse´s death due to cancer - a randomized intervention
Swedish Research Council
1 January 2015 - 31 December 2017

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2024-2026

Degrees and Education

Docent, Karolinska Institutet, 2016
Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2002
University Medical Degree, Karolinska Institutet, 1999

About me

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI